Serum creatine kinase levels in chronic psychosis patients - a comparison between atypical and conventional antipsychotics

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 30, Issue 7, 2006, Pages 1277-1282

  Melkersson, Kristina ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Antipsychotic agents; Clozapine; Creatine kinase; Olanzapine; Psychotic disorder

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; CREATINE KINASE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATINE KINASE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; HUMAN; MALE; PARANOID SCHIZOPHRENIA; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLOZAPINE; CREATINE KINASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS;

EID: 33747308393     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2006.04.025     Document Type: Article

References (65)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. (1994), American Psychiatric Press, Washington, DC
2. Baumgart U., Schmid R., and Spiebl H. Olanzapine-induced acute rhabdomyolysis [letter]. Pharmacopsychiatry 38 (2005) 36-37
3. Bengzon A., Hippius H., and Kanig K. Some changes in the serum during treatment with psychotropic drugs. J Nerv Ment Dis 143 (1966) 369-376
4. Blanchet P.J. Antipsychotic drug-induced movement disorders. Can J Neurol Sci 30 suppl. 1 (2003) S101-S107
5. Blumensohn R., Yoran-Hegesh R., Golubchik P., Mester R., Fluhr H., Hermesh H., et al. Elevated serum creatine kinase activity in adolescent psychiatric inpatients on admission. Int Clin Psychopharmacol 13 (1998) 269-272
6. Catlow J.T., Barton R.D., Clemens M., Gillespie T.A., Goodwin M., and Swanson S.P. Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Appl 668 (1995) 85-90
7. Cavanaugh J.J., and Finlayson R.E. Rhabdomyolysis due to acute dystonic reaction to antipsychotic drugs. J Clin Psychiatry 45 (1984) 356-357
8. Coffey J.W., Heath R.G., and Guschwan A.F. Serum creatine kinase, aldolase, and copper in acute and chronic schizophrenics. Biol Psychiatry 2 (1970) 331-339
9. Dahl M.L., Ekqvist B., Widen J., and Bertilsson L. Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans. Acta Psychiatr Scand 84 (1991) 99-100
10. Devarajan S., and Dursun S.M. Antipsychotic drugs, serum creatine kinase (CPK) and possible mechanisms [letter]. Psychopharmacology 152 (2000) 122
11. Dubo H., Park D.C., Pennington R.J.T., Kalbag R.M., and Walton J.N. Serum-creatine-kinase in cases of stroke, head injury, and meningitis. Lancet 2 (1967) 743-748
12. Egan M.F., Dargham A.A., Kirch D.G., and Wyatt R.J. Serum creatine phosphokinase elevations in patients with tardive dyskinesia. Br J Psychiatry 162 (1993) 551-553
13. Eng C., Skolnick A.E., and Come S.E. Elevated creatine kinase and malignancy. Hosp Pract 25 (1990) 123-130
14. Faulstich M.E., Brantley P.J., and Barkemeyer C.A. Creatine phophokinase, the MMPI, and psychosis. Am J Psychiatry 141 (1984) 584-586
15. Flemming Bjørndahl A., Lauritsen B., Lyngbye J., and Waarst S. Serum creatine kinase in patients receiving long-acting antipsychotics. Ugeskr Laeg 141 (1979) 3514-3516
16. Gosling R., Kerry R.J., Orme J.E., and Owen G. Creatine phosphokinase activity in newly admitted psychiatric patients. Br J Psychiatry 121 (1972) 351-355
17. Gosling R., Kerry R.J., and Owen G. Creatine phosphokinase activity during lithium treatment. Br Med J 3 (1972) 327-329
18. Graig F.A., and Ross G. Serum creatine-phosphokinase in thyroid disease. Metabolism 12 (1963) 57-59
19. Graig F.A., and Smith J.C. Serum creatine phosphokinase activity in altered thyroid states. J Clin Endocrinol 25 (1965) 723-731
20. Griffiths P.D. Serum levels of ATP: creatine phosphotransferase (creatine kinase). The normal range and effect of muscular activity. Clin Chim Acta 13 (1966) 413-420
21. Harding T. Serum creatine kinase in acute psychosis. Br J Psychiatry 125 (1974) 280-285
22. Hess J.W., MacDonald R.P., Frederick R.J., Jones R.N., Neely J., and Gross D. Serum creatine phosphokinase (CPK) activity in disorders of heart and skeletal muscle. Ann Intern Med 61 (1964) 1015-1028
23. Jung H.H., and Brandner S. Malignant McLeod myopathy. Muscle Nerve 26 (2002) 424-427
24. Ka T., Takahashi S., Tsutsumi Z., Moriwaki Y., Yamamoto T., and Fukuchi M. Hyperosmolar non-ketotic diabetic syndrome associated with rhabdomyolysis and acute renal failure: a case report and review of literature. Diab Nutr Metab 16 (2003) 317-322
25. Keshavan M.S., Stecker J., and Kambhampati R.K. Creatine kinase elevations with clozapine. Br J Psychiatry 164 (1994) 118-120
26. Kirson J.I., McQuistion H.L., and Pierce D.W. Severe elevations in serum creatine kinase associated with clozapine [letter]. J Clin Psychopharmacol 15 (1995) 287-288
27. Klein D. Case report: HyperCKemia: a diagnostic dilemma. Can Fam Physician 51 (2005) 240-241
28. Koren W., Koren E., Nacasch N., Ehrenfeld M., and Gur H. Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes. Clin Neuropharmacol 21 (1998) 262-264
29. Lafair J.S., and Myerson R.M. Alcoholic myopathy - with special reference to the significance of creatine phosphokinase. Arch Intern Med 122 (1968) 417-422
30. Larsson M., and Forsman A. A high-performance liquid chromatographic method for the assay of perphenazine and its dealkylated metabolite in serum after therapeutic doses. Ther Drug Monit 5 (1983) 225-228
31. Levenson J.L. Neuroleptic malignant syndrome. Am J Psychiatry 142 (1985) 1137-1145
32. Llerena A., Alm C., Dahl M.L., Ekqvist B., and Bertilsson L. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit 14 (1992) 92-97
33. Lui W.Y. Phenothiazine-induced dystonia associated with an increase in serum creatine phosphokinase. Arch Dis Child 54 (1979) 150-151
34. Marcus E.-L., Vass A., and Zislin J. Marked elevation of serum creatine kinase associated with olanzapine therapy. Ann Pharmacother 33 (1999) 697-700
35. Marti-Bonmati E., San Valero-Carcelen E., Ortega-Garcia M.P., and Rubini-Puig R. Olanzapine elevation of serum creatine kinase [letter]. J Clin Psychiatry 64 (2003) 483-484
36. Melkersson K.I., and Dahl M.-L. Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses. Psychopharmacology 170 (2003) 157-166
37. Melkersson K.I., Hulting A.-L., and Rane A. Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses. Br J Clin Pharmacol 51 (2001) 317-324
38. Meltzer H.Y. Creatine kinase and aldolase in serum: abnormality common to acute psychoses. Science 159 (1968) 1368-1370
39. Meltzer H.Y. Factors affecting serum creatine phosphokinase levels in the general population: the role of race, activity and age. Clin Chim Acta 33 (1971) 165-172
40. Meltzer H.Y. Creatine phosphokinase activity and clinical symptomatology. A study in acute schizophrenic patients. Arch Gen Psychiatry 29 (1973) 589-593
41. Meltzer H.Y. Neuromuscular dysfunction in schizophrenia [review]. Schizophr Bull 2 (1976) 106-135
42. Meltzer H.Y. Massive serum creatine kinase increases with atypical antipsychotic drugs: what is the mechanism and the message?. Psychopharmacology 150 (2000) 349-350
43. Meltzer H., Elkun L., and Moline R.A. Serum-enzyme changes in newly admitted psychiatric patients. Part I. Arch Gen Psychiatry 21 (1969) 731-738
44. Meltzer H.Y., Grinspoon L., and Shader R.I. Serum creatine phosphokinase and aldolase activity in acute schizophrenic patients and their relatives. Comphr Psych 11 (1970) 552-558
45. Meltzer H.Y., Mrozak S., and Boyer M. Effect of intramuscular injections on serum creatine phosphokinase activity. Am J Med Sci 259 (1970) 42-48
46. Meltzer H.Y., Nankin R., and Raftery J. Serum creatine phosphokinase activity in newly admitted psychiatric patients. Part II. Arch Gen Psychiatry 24 (1971) 568-572
47. Meltzer H.Y., Dorus E., Grunhaus L., Davis J.M., and Belmaker R. Genetic control of human plasma creatine phosphokinase activity. Clin Genet 13 (1978) 321-326
48. Meltzer H.Y., Cola P.A., and Parsa M. Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment. Neuropsychopharmacology 15 (1996) 395-405
49. Nair V., Hariprasad M.K., and Weiss A. Lithium carbonate, hypothyroidism, and serum creatine phosphokinase level [letter]. JAMA 243 (1980) 1231-1232
50. Perlov E., Tebartz van Elst L., Czygan M., Bubl E., and Ebert D. Serum creatine kinase elevation as a possible complication of therapy with olanzapine. Naunyn Schmiedeberg's Arch Pharmacol 327 (2005) 168-169
51. Reznik I., Volchek L., Mester R., Kotler M., Sarova-Pinhas I., Spivak B., et al. Myotoxicity and neurotoxicity during clozapine treatment. Clin Neuropharmacol 23 (2000) 276-280
52. Rosebraugh C.J., Flockhart D.A., Usdin Yasuda S., and Woosley R.L. Olanzapine-induced rhabdomyolysis. Ann Pharmacother 35 (2001) 1020-1023
53. Scelsa S.N., Simpson D.M., McQuistion H.L., Fineman A., Ault K., and Reichler B. Clozapine-induced myotoxicity in patients with chronic psychotic disorders. Neurology 47 (1996) 1518-1523
54. Schiavone D.J., and Kaldor J. Creatine phosphokinase levels and cerebral disease. Med J Aust 2 (1965) 790-792
55. Schubert D.S.P., Brocco K., Miller F., and Patterson M. Brief and mild alcohol intake can increase serum creatine phosphokinase [letter]. Ann Neurol 9 (1981) 200-201
56. Schwartz C.M., and Breen K.J. Multiple muscle enzyme release with psychiatric illness. J Nerv Ment Dis 178 (1990) 755-759
57. Siegel S., and Castellan N.J. Multiple comparisons between treatments. Nonparametric statistics for the behavioral sciences. 2nd ed. (1988), McGraw-Hill Book Company, New York 213-214
58. Skogh E., Reis M., Dahl M.-L., Lundmark J., and Bengtsson F. Therapeutic drug monitoring data on olanzapine and its N-dimethyl metabolite in the naturalistic clinical setting. Ther Drug Monit 24 (2002) 518-526
59. Thompson P.D., Clarkson P., and Karas R.H. Statin-associated myopathy. JAMA 289 (2003) 1681-1690
60. Van der Veen K.J., and Willebrands A.F. Isoenzymes of creatine phosphokinase in tissue extracts and in normal and pathological sera. Clin Chim Acta 13 (1966) 312-316
61. Warren J.D., Blumberghs P.C., and Thompson P.D. Rhabdomyolysis: a review [review]. Muscle Nerve 25 (2002) 332-347
62. Willis J.K., Tilton A.H., Harkin J.C., and Boineau F.G. Reversible myopathy due to labetalol. Pediatr Neurol 6 (1990) 275-276
63. Wolintz A.H., Jacobs L.D., Christoff N., Solomon M., and Chernik N. Serum and cerebrospinal fluid enzymes in cerebrovascular disease. Arch Neurol 20 (1969) 54-61
64. Wyss M., and Kaddurah-Daouk R. Creatine and creatinine metabolism [review]. Physiol Rev 80 (2000) 1107-1213
65. Yasui N., Tybring G., Otani K., Mithara K., Suzuki A., Svensson J.-O., et al. Effects of thioridazine, an inhibitor of CYP2D6, on the steady-state plasma concentrations of the enantiomers of mianserin and its active metabolite, desmethylmianserin, in depressed Japanese patients. Pharmacogenetics 7 (1997) 369-374